CAMERA: Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
Study Details
Study Description
Brief Summary
This single-arm, Phase II study was designed to evaluate the safety and efficacy of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) combination with Apatinib in participants with ES-SCLC who was response or stable disease after firstline standard chemotherapy. Participants will be receive camrelizumab +apatinib on 21-day cycles until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Camrelizumab Plus Apatinib camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally |
Drug: Camrelizumab Plus Apatinib
-Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.
Other Name: SHR-1210
-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD.
|
Outcome Measures
Primary Outcome Measures
- Progression free survival(PFS) [up to 12 months]
From the date of maintenance randomization to the date of first document of progression or symptomatic deterioration, or death due to any cause
Secondary Outcome Measures
- Overall survival(OS) [up to 24 months]
From the date of maintenance randomization until death from any cause, with participants last known to be alive censored at the date of last contact
Other Outcome Measures
- Adverse events (AEs) [up to 24 month]
All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 5.0
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female patients aged 18 and 75 years old;
-
Signed the informed consent form prior to patient entry;
-
Eastern Cooperative Oncology Group performance status of 0 or 1;
-
Expected Survival Time: Over 3 months;
-
Pathological or cytologically proven extensive-Stage small cell lung cancer(according to Veterans Administration Lung Study Group)and without progression after Cycles 4-6 21-day cycles of first-line Standard chemotherapy(Evaluation was CR /PR/SD based on RECIST1.1);
-
If prophylactic cranial irradiation (PCI) was not planned,informed consent was required to be written between 3 weeks and 5 weeks after day 1 of the last cycle of chemotherapy. If PCI was planned or already performe, informed consent was required to be written between 3 weeks and 8 weeks after day 1 of the last cycle of chemotherapy.
Exclusion Criteria:
-
Has prior therapy with anti-programmed cell death (PD)-1, anti-PD-L1,anti Cytotoxic T lymphocyte-associated Antigen(CTLA)-4 or other Drugs that target T cells;
-
Has prior therapy with angiogenesis inhibitors,Such as sunitinib, bevacizumab, apatinib, anlotinib;
-
Has active or untreated central nervous system (CNS) metastases and/or cancerous meningitis;
-
Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary with blood vessels is unclear;
-
Has spinal cord compression which was not cured or relieved through surgery and/or radiotherapy, or diagnosed spinal cord compression after treatment showed no clinical evidence of disease stabilization prior to allocation ≥1 week;
-
Within the past 2 weeks have used high dose antibiotics;
-
According to the judgement of the researchers, there are other factors that may lead to the termination of the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Henan Cancer Hospital | Zhengzhou | Henan | China | 450000 |
Sponsors and Collaborators
- Henan Cancer Hospital
Investigators
- Principal Investigator: Qiming Wang, Doctor, Henan Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MA-SCLC-Ⅱ-002